News | May 25, 2026
Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Safety was equally impressive. ENV-294 was well tolerated
Subscribe To Our Newsletter & Stay Updated
